Concentration of Soluble Adhesion Molecules (sVCAM-1, sICAM-1 and sL-Selectin) in the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis and Systemic Lupus erythematosus with Central Nervous Involvement

Baraczka, Krisztina; Nékám, K; Pozsonyi, T; Jakab, L; Szongoth, M; Seszták, Magdolna

doi:10.1159/000049007

Cited by 44 publications

(24 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consequently ICAM-1 is normally detected bound to the membrane. However, soluble forms of the protein, mainly representing the extracellular N-terminal fragment of the protein have been detected in vivo and in vitro (Baraczka et al, 2001;Rothlein et al, 1991;Seth et al, 1991). In our immunohistochemical studies a large portion of non-vascular ICAM-1-I although always associated with the region of tissue reached by GFAP-IR processes, presents a diffuse pattern of distribution in the neuropil.…”

Section: Discussionmentioning

confidence: 54%

Distribution of ICAM-1 immunoreactivity during aging in the human orbitofrontal cortex

Miguel-Hidalgo

Nithuairisg

Stockmeier

et al. 2007

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Neurological and psychiatric alterations during aging are associated with increased cerebrovascular disturbances and inflammatory markers such as Intercellular Adhesion Molecule-1 (ICAM-1). We investigated whether the distribution of ICAM-1 immunoreactivity (ICAM-1-I) in histological sections from the left orbitofrontal cortex (ORB) was altered during normal aging. Postmortem tissue from the ORB of nine younger (27-54 years old) and 10 older (60-86) human subjects was collected. Cryostat sections were immunostained only with antibodies to ICAM-1 or together with an antibody to glial fibrillary acidic protein (GFAP). The total area fraction of ICAM-1-I, and the fraction of vascular and extravascular ICAM-1-I were quantified in the gray matter. Furthermore, we examined the association of extravascular ICAM-1-I to GFAP immunoreactive (GFAP-IR) astrocytes. In all subjects, brain blood vessels were similarly ICAM-1 immunoreactive, and in some subjects there was a variable number of extravascular patches of ICAM-1-I. The area fraction of ICAM-1-I was 120% higher (p < .0001) in the old subjects than in the young subjects. This increase localized mostly to the extravascular ICAM-1-I in register with GFAP-IR astrocytes. A much smaller, also age-dependent increase occurred in vascular ICAM-1-I. Our results indicate a dramatic increase in extravascular ICAM-1-I associated to GFAP-IR astrocytes in the ORB in normal aging. This increase may contribute to an enhanced risk for brain inflammatory processes during aging, although a role of extravascular ICAM-1 as a barrier to further inflammation cannot be ruled out.

show abstract

Section: Discussionmentioning

confidence: 54%

Distribution of ICAM-1 immunoreactivity during aging in the human orbitofrontal cortex

Miguel-Hidalgo

Nithuairisg

Stockmeier

et al. 2007

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

show abstract

“…These observed features likely reflect the end result of repeated episodes of acute inflammation in the small vessels of the brain (Hess, 1997). Soluble adhesion molecules found in serum and CSF of patients with central nervous involvement (Baraczka et al, 2001) also suggests that neuroinflammatory conditions may play an understated role in some NP manifestations.…”

Section: Evidence Of Neuroinflammation In Cns Diseasementioning

confidence: 99%

Neuroimmunopathology in a murine model of neuropsychiatric lupus

Ballok

2007

Brain Research Reviews

View full text Add to dashboard Cite

Animal models are extremely useful tools in defining pathogenesis and treatment of human disease. For many years researchers believed that structural damage to the brain of neuropsychiatric (NP) patients lead to abnormal mental function, but this possibility was not extensively explored until recently. Imaging studies of NP-systemic lupus erythematosus (SLE) support the notion that brain cell death accounts for the emergence of neurologic and psychiatric symptoms, and evidence suggests that it is an autoimmunity-induced brain disorder characterized by profound metabolic alterations and progressive neuronal loss. While there are a number of murine models of SLE, this article reviews recent literature on the immunological connections to neurodegeneration and behavioral dysfunction in the Fas-deficient MRL model of NP-SLE. Probable links between spontaneous peripheral immune activation, the subsequent central autoimmune/inflammatory responses in MRL/MpJ-Tnfrsf6 lpr (MRL-lpr) mice and the sequential mode of events leading to Fas-independent neurodegenerative autoimmune-induced encephalitis will be reviewed. The role of hormones, alternative mechanisms of cell death, the impact of central dopaminergic degeneration on behavior, and germinal layer lesions on developmental/regenerative capacity of MRL-lpr brains will also be explored. This model can provide direction for future therapeutic interventions in patients with this complex neuroimmunological syndrome.

show abstract

“…Soluble ICAM-1 (sICAM-1) is an indirect parameter of increased ICAM-1 expression on activated immune or endothelial cells. In inflammatory neurological diseases, elevated levels of soluble ICAM-1 are assumed to be an indicator for an impairment of the BBB, with an increased invasion of macrophages/microglia or cytokines in the central nervous system [4,5,6]. Elevated blood levels of the cell adhesion molecule ICAM-1 have been shown to be associated with depressive mood states in elderly patients, patients with vascular-related depression, or patients with depression during immune treatment [7,8,9,10].…”

Section: Introductionmentioning

confidence: 99%

Soluble Intracellular Adhesion Molecule-1 in Patients with Unipolar or Bipolar Affective Disorders: Results from a Pilot Trial

et al. 2016

View full text Add to dashboard Cite

Background: Immunological and vascular markers may play a role in the pathophysiology of mood disorders and mood changes. Aim: To test whether the cell adhesion molecule soluble intracellular adhesion molecule-1 (sICAM-1) may serve as a biomarker for patients with unipolar or bipolar affective disorders when compared to a healthy control group, and whether sICAM-1 blood levels change during different mood states. Methods: sICAM-1 serum concentrations were compared between 20 healthy controls and 48 patients with affective disorders (unipolar, bipolar II and bipolar I disorder) during different mood states (euthymic mood state, depression or mania). Results: When compared to healthy controls, patients with affective disorders had significantly higher sICAM-1 levels during the euthymic state (p = 0.015). Differences became more pronounced during depression (p = 0.013). When unipolar and bipolar patients were analyzed separately, unipolar patients significantly differed from controls during the euthymic and depressive mood state, while bipolar II patients showed a trend towards higher sICAM-1 levels during depression. Patients with bipolar I disorders had significantly higher sICAM-1 levels during manic states when compared to controls (p = 0.007). Conclusions: sICAM-1 elevation in unipolar and bipolar patients, independent of mood changes, might support the hypothesis of chronic immune activation and endothelial dysfunction in patients with affective disorders.

show abstract

Concentration of Soluble Adhesion Molecules (sVCAM-1, sICAM-1 and sL-Selectin) in the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis and Systemic Lupus erythematosus with Central Nervous Involvement

Cited by 44 publications

References 3 publications

Distribution of ICAM-1 immunoreactivity during aging in the human orbitofrontal cortex

Distribution of ICAM-1 immunoreactivity during aging in the human orbitofrontal cortex

Neuroimmunopathology in a murine model of neuropsychiatric lupus

Soluble Intracellular Adhesion Molecule-1 in Patients with Unipolar or Bipolar Affective Disorders: Results from a Pilot Trial

Contact Info

Product

Resources

About